Applications of LDL-apheresis in nephrology

Clinical and Experimental Nephrology

Volumn 12, Issue 1, 2008, Pages 9-15

  Kobayashi, Shuzo ^a  

^a SHONAN KAMAKURA GENERAL HOSPITAL   (Japan)

Author keywords

Apheresis; Diabetic nephropathy; Inflammation; LDL; Peripheral arterial disease (PAD); Proteinuria

Indexed keywords

BRADYKININ; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; CHOLESTEROL; CYCLOSPORIN; DEXTRAN SULFATE; GLUCOCORTICOID RECEPTOR; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 8; LOW DENSITY LIPOPROTEIN; NITRIC OXIDE; PADGEM PROTEIN; PROSTANOID; STEROID; THROMBOXANE A2; TRIACYLGLYCEROL; VASCULOTROPIN; VERY LOW DENSITY LIPOPROTEIN;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; APHERESIS; ARTERY DISEASE; ATHEROSCLEROSIS; BLOOD RHEOLOGY; BLOOD SUBSTITUTION; CHOLESTEROL BLOOD LEVEL; CYTOKINE RELEASE; DIABETIC NEPHROPATHY; DISEASE COURSE; DISEASE SEVERITY; DRUG BINDING; ENDOTHELIAL DYSFUNCTION; FAMILIAL HYPERLIPEMIA; FOCAL GLOMERULOSCLEROSIS; HUMAN; KIDNEY FAILURE; LDL APHERESIS; LIPID BLOOD LEVEL; LYMPHOCYTE; MACROPHAGE; NEPHROTIC SYNDROME; PATHOPHYSIOLOGY; PLASMAPHERESIS; PROTEIN BLOOD LEVEL; PROTEINURIA; REVIEW; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

AMYLOIDOSIS; APOLIPOPROTEINS B; ATHEROSCLEROSIS; BLOOD COMPONENT REMOVAL; DIABETIC NEPHROPATHIES; GLUCOCORTICOIDS; HUMANS; LIPOPROTEINS, LDL; NEPHROTIC SYNDROME; P-SELECTIN; PERIPHERAL VASCULAR DISEASES; RECEPTORS, GLUCOCORTICOID; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 38549096157     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-007-0003-8     Document Type: Review

References (61)

1. Thompson GR, Lowenthal R, Myant NB. Plasma exchange in the management of homozygous familial hypercholesterolaemia. Lancet. 1975;I:1208-11.
2. Stoffel W, Borberg H, Greve V. Application of specific extracorporeal removal of low-density lipoprotein in familial hyperlipidemia. Lancet. 1981;ii:1005-7.
3. Yokoyama S,Hayashi R, Satani M, Yamamoto A. Selective removal of low density lipoprotein by plasmapheresis in familial hypercholesterolemia. Arteriosclerosis. 1985;5:613-21.
4. Saal SD, Parker TS, Gordon BR, Studebaker J, Hudgins L, Ahrens EH Jr, Rubin AL: Removal of low-density lipoproteins in patients by extracorporeal immunoadsorption. Am J Med. 1986;80:583-9.
5. Knisel W, Di Nicuolo A, Pfohl M, Muller H, Risler T, Eggstein M, Seifried E. Different effects of two methods of low-density lipoprotein apheresis on the coagulation and fibrinolytic systems. J Int Med. 1993;234:479-87.
6. Bosch T, Lennertz A, Schmidt B. DALI apheresis in hyperlipidemic patients: biocompatibility, efficacy, and selective of direct adsorption of lipoproteins from whole blood. Artif Organs. 2000;24:81-90.
7. Kobayashi S, Moriya H, Negishi K, Maesato K, Ohtake T. LDL-apheresis up-regulates VEGF and IGF-I in patients with ischemic limb. J Clin Apheresis. 2003;18:115-9.
8. O'Hare A, Johansen K. Lower-extremity peripheral arterial disease among patients with end-stage renal disease. J Am Soc Nephrol. 2001;12:2838-47.
9. Thompson GR, Myant NB, Kilpatrick D, Oakley CM, Raphael MJ, Steiner RE. Assessment of long-term plasma-exchange for familial hypercholesteromia. Br Heart J. 1980;43:680-90.
10. Rubba P, Postiglione A, Scarpato N, Iannuzzi A, Mancini M. Improved reactive hyperemia test after plasma exchange in familial hypercholesteromia. Atherosclerosis. 1985;56:237-42.
11. Agishi T, Kitano Y, Suzuki T, Miura A, Murakami J, Minagawa H. Improvement of peripheral circulation by low density lipoprotein adsorption. Trans Am Soc Artif Intern Organs. 1989;35:349-51.
12. Agishi T, Naganuma S, Nakasato S, Kitajima K, Ota K, Ban K. Treatment of arteriosclerotic obstruction by LDL adsorption. Angiology. 1993;44:222-7.
13. Kroon AA, Aengevaeren WR, van der Werf T, Uijen GJ, Reiber JH, Bruschke AV, Stalenhoef AF. The LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation. 1996;93:1826-35.
14. Kobayashi S. LDL-aphereis for diabetic nephropathy: a possible new tool. Nephron. 1998;79:505-6.
15. Mii S, Mori A, Sakata H, Nakayama M, Tsuruta H. LDL-apheresis for arteriosclerosis obliterans with occluded bypass graft: change in prostacyclin and effect on ischemic syndrome. Angiology. 1998;49:175-80.
16. Koenig W, Ditschuneit HH, Grunewald RW, Ernst E, Hombach V. Blood rheology after apheresis using dextran sulfate cellulose absorption-a case report. Angiology. 1992;43:606-9.
17. Naganuma S, Agishi T, Ota K. Hemorheological effects of low density lipoprotein apheresis on atherosclerosis disease with hyperlipidemia. Therap Plasm. 1993;12:443-5.
18. Murashima J, Ueki Y, Matsunaga Y, Yano M, Matsumoto K, Miyake S, Tominaga Y, Eguchi K, Yano K. Removal of low-density lipoprotein from plasma by adsorption increases bradykinin and plasma nitric oxide levels in patients with peripheral atherosclerosis. Blood Coag Fibrinol. 1998;9:725-32.
19. Uno H, Ueki Y, Murashima J, Miyake S, Tominaga Y, Eguchi K, Yano K. Removal of LDL from plasma by adsorption reduces adhesion molecules on mononuclear cells in patients with arteriosclerotic obliterans. Atherosclerosis. 1995;116:93-02.
20. Tamai O, Matsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation. 1997;95:76-82.
21. Nakamura T, Matsuda T, Suzuki Y, Ueda Y, Koide H. Effects of low-density lipoprotein apheresis on plasma matrix metalloproteinase-9 and serum tissueinhibitor of metalloproteinase-1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans. ASAIO J. 2003;49:430-4.
22. Kojima S, Shida M, Tanaka K, Takano H, Yokoyama H, Kuramochi M. Acute changes in plasma levels of hepatocyte growth factor during low-density lipoprotein apheresis. Therap Apheresis. 2001;5:2-6.
23. Ferrara N, Gerber HP. The role of vascular endothelial growth factor in angiogenesis. Acta Haematol. 2001;106:148-56.
24. Zapf J, Froesch ER. Insulin-like growth factor/somatomedins: structures, secretion, biological actions and physiological role. Horm. Res. 1986;24:121-30.
25. Hansson H, Jennische E, Skottner A. Regenerating endothelial cells express insulin-like growth factor-I immunoreactivity after arterial injury. Cell Tissue Res. 1987;250:499-05.
26. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 1997;18:4-25.
27. Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int. 1999;56:794-14.
28. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986;315:1650-9.
29. 165 in patient with ischaemic limb. Lancet. 1996;348:370-4.
30. Tsukahara H, Gordienko DV, Tonshoff B, Gelato MC, Goligorsky MS. Direct demonstration of insulin-like growth factor-I-induced nitric oxide production by endothelial cells. Kidney Int. 1994;45:598-604.
31. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340:115-26.
32. Schachinger V, Zeiher AM. Atherosclerosis-recent insight into basic mechanisms and their clinical impact. Nephrol Dial Trans. 2002;17:2055-64.
33. Verma S, Buchanan MR, Anderson TJ. Endothelial function. Testing as a biomarker of vascular disease. Circulation. 2003;108:2054-9.
34. Burger PC, Wagner DD. Platelet P-selectin fascilitates atherosclerotic lesion development. Blood. 2003;101:2661-6.
35. Blann AD, Lip GYH. Hypothesis: is soluble P-selectin a new marker of platelet activation? Atherosclerosis. 1997;128:135-8.
36. Kobayashi S, Oka M, Moriya H, Maesato K, Okamoto K, Ohtake T. LDL-apheresis reduces P-selectin, CRP and fibrinogen- possible implications for improving atherosclerosis. Ther Apher Dial. 2006;10:219-23.
37. Matsuzaki M, Hiramori K, Imaizumi T, Kitabatake A, Hishida H, Nomura M, Fujii T. Intravenous ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia. The low density lipoprotein-apheresis coronary morphology and reserve trial (LACMART). J Am Coll Cardiol. 2002;40:220-7.
38. Beer FC, Soutar AK, Baltz ML, Trayner IM, Feinstein A, Pepys MB: Low density lipoprotein and very low density protein are selectively bound by aggregated C-reactive protein. J Exp Med. 1982;230-42
39. Utsumi K, Kawabe M, Hirayama A, Ueda K, Kamada Y, Aril K, Komaba Y, Katsura KI, Iino Y, Katayama Y. Effects of selective LDL apheresis on plasma concentration of ICAM-1, VCAM-1 and P-selectin in diabetic patients with arteriosclerosis obliterans and receiving maintenance hemodialysis. Clin Chim Acta 2006;Oct 6 (E-pub).
40. Savin VJ, Sharma R, Sharma M, McCarthy ET, Swan SK, Ellis E, Lovell H, Warady B, Gunwar S, Chonko AM, Artero M, Vincenti F. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med. 1996;334:878-83.
41. Tojo K, Sakai S, Miyahara T. Possible therapeutic application of low density lipoprotein apheresis in conjunction with double filtration plasma pheresis in drug-resistant nephrotic syndrome due to focal glomerular sclerosis. Jpn J Nephrol. 1988;30:1153-60.
42. Yokoyama K, Sakai S, Yamamoto H, Tojo K, Tada N, Suzuki M, Sakai O. Therapeutic LDL apheresis in patients with drug-resistant nephrotic syndrome and severe glomerular nephritis with hyperlipidemia. In: Ohta et al. (ed) Plasmapheresis. Cleveland: ISAIO Press, 1990. Vol 9, p. 50-5.
43. Yokoyama K, Sakai S, Yamaguchi Y, Suzuki Y, Hinoshita F, Hara S, Yamada A, Ogura Y, Kawaguchi Y, Sakai O. Complete remission of the nephrotic syndrome due to focal glomerular sclerosis achieved with LDL adosorption alone. Nephron. 1996;72:318-20.
44. Muso E, Yashiro M, Matsusia M, Yoshida H, Sawanishi K, Sasayama S. Does LDL-apheresis in steroid-resistant nephrotic syndrome affect prognosis? Nephrol Dial Trans. 1994;9:257-64.
45. Yokoyama K, Sakai S, Shigematsu T, Takemoto F, Hara S, Yamada A, Kawaguchi Y, Hosoya T. LDL adsorption improves the response of focal glomerulosclerosis to corticosteroid therapy. Clini Nephrol. 1998;50:1-7.
46. Muso E, Mune M, Fujii Y, Imai E, Ueda N, Hatta K, Imada A, Miki S, Kuwahara T, takamitsu Y, Takemura T, Tsubakihara Y, for the Kansai-FGS-Apheresis Treatment (K-FLAT) Stusy Group. Low density lipoprotein apheresis therapy for steroid-resistant nephrotic syndrome. Kidney Int. 1999;56:S122-5.
47. Muso E, Mune M, Fujii Y, Imai E, Ueda N, Hatta K, Imada A, Miki S, Kuwahara T, takamitsu Y, Takemura T, Tsubakihara Y, for the Kansai-FGS-Apheresis Treatment (K-FLAT) Study Group. Significantly rapid relief from ateroid-resistant nephrotic syndrome by LDL apheresis compared with steroid monotherapy. Nephron 2001;89:408-15.
48. Hattori M, Chikamoto H, Akioka Y, Nakakura H, Ogino D, Matsunaga A, Hukazawa A, Miyakawa S, Khono M, Kawaguchi H, Ito K. A combined low-density lipoprotein apheresis and prednisone therapy for steroid-resistant primary focal segmental glomerulosclerosis in children. Am J Kidney Dis. 2003;42:1121-30.
49. Sakurai M, Muso E, Matsushita H, Ono T, Sasayama S. Rapid normalization of interleulin-8 production after low-density lipoprotein apheresis in steroid-resistant nephrotic syndrome. Kidney Int. 1999;56:S210-2.
50. Nakao T, Yoshino M, Matsumoto H, Okada T, Han M, Hidaka H, Shino T, Yamada C, Nagaoka Y, Miyahara T. Low-density lipoprotein apheresis retards the progression of hyperlipidemic overt diabetic nephropathy. Kidney Int. 1999;71:S206-9.
51. Nakamura T, Kawagoe Y, Ogawa H, Ueda Y, Hara M, Shimada N, Ebihara I, Koide H. Effect of low-density lipoprotein apheresis on urinary protein and podocyte excretion in patients with nephrotic syndrome due to diabetic nephropathy. Am J Kidney Dis. 2004;45:48-53.
52. Pagtalunan ME, Miller PL, Jumping-Eagle S. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest. 1997;99:342-8.
53. White KE, Bjlous RW, Diabiopsies Study Group: Structural alterations to the podocyte are related to proteinuria in type 2 diabetic patients. Nephrol Dial Trans 2004;19:1437.
54. Inoue I, Kikuchi C, Takahashi K, Katayama S. LDL apheresis reduces the susceptibility of LDL to in vitro oxidation in a diabetic patient with hemodialysis treatment. Diabetes Care 1996;1103-7.
55. Petrichenko I, Daret D, Larrue J, Shakhov Y. Effect of VLDL on the inhibition of arachidonic acid transformation by dexamethasone in cultured smooth muscle cells. Biochem Biophys Acta. 1993;1166:183-7.
56. De Groen PC. Cyclosporine, low-density lipoprotein, and cholesterol. Mayo Clin Proc. 1988;63:1012-1021.
57. Fine MJ, Kapoor W, Falanga V. Cholesterol crystal embolization: a review of 221 cases in the English literature. Angiology. 1987;38:769-84.
58. Belenfant X, Meyrier A, Jacquot C. Supportive treatment improves survival in multivisceral cholesterol crystal embolism. Am J Kidney Dis. 1999;33:840.
59. Tsunoda S, Daimon S, Miyazaki R, Fujii H, Inazu A, Mabuchi H. LDL apheresis as intensive lipid-lowering therapy for cholesterol embolism. Nephrol Dial Transplant. 1999;14:1041-2.
60. Daimon S, Motita R, Ohtsuki N, Chiaki H, Jigen K, Koni I. LDL apheresis followed by corticosteroid therapy as a possible treatment of cholesterol crystal embolism. Clin Exp Nephrol. 2000;4:352-5.
61. Iwahori T, Yoshida M. Low-density lipoprotein apheresis can improve type AA systemic amyloidosis. Nephron. 2000;86:248-50.